Cargando…
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
Patients with platinum-resistant ovarian cancer have progression of disease within 6 months of completing platinum-based chemotherapy. While several chemotherapeutic options exist for the treatment of platinum-resistant ovarian cancer, the overall response to any of these therapies is ~10%, with a m...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803258/ https://www.ncbi.nlm.nih.gov/pubmed/27051317 http://dx.doi.org/10.2147/IJWH.S78101 |